Oculis Holding AG (OCS), a clinical-stage biopharmaceutical, announced on Monday the completion of the final patient visit in the Phase 3 DIAMOND program of OCS-01,it's lead investigational eye drop in diabetic macular edema or DME. Oculis expects to report topline results in June 2026.
OCS-01 is a high-concentration dexamethasone eye drop formulation developed to treat the retina for diabetic macular oedema. The DIAMOND program consists of two Phase 3 trials named DIAMOND-1 and DIAMOND-2, randomised, double-masked, multicenter studies evaluating the efficacy and safety of OCS-01 over 52 weeks.
Oculis enrolled over 800 patients across both pivotal trials, who were randomised 1:1 to receive OCS-01 or vehicle administered six times daily during a 6-week induction phase, followed by three times daily dosing through week 52.
The firm estimated 1 million patients out of the 1.8 million people diagnosed with DME in the U.S. remain untreated or underserved.
Beyond OCS-01, Oculis' late-stage pipeline includes Privosegtor (OCS-05) in the PIONEER program for optic neuropathies such as optic neuritis and non-arteritic anterior ischemic optic neuropathy or NAION, and Licaminlimab in a registrational trial for dry eye disease.
As of December 31, the firm had cash, cash equivalents, and short-term investments of $268.7 million and expects a cash runway into 2029.
OCS has traded between $16 and $30.68 over the last year. The stock closed Friday's trade at $27.46, up 0.33%.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.